Patents by Inventor Larry W. Tjoelker

Larry W. Tjoelker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250122309
    Abstract: In one aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, comprising a bioactive peptide amino acid sequence, wherein the bioactive peptide amino acid sequence is an inhibitor of the complement system and is fused to at least one of: (i) the amino terminal region of at least one of: a light chain variable region and/or a heavy chain variable region; or (ii) the carboxy terminal region of at least one of: a light chain constant region and/or a heavy chain constant region, wherein the antibody inhibits complement activation.
    Type: Application
    Filed: September 27, 2024
    Publication date: April 17, 2025
    Inventors: W. Jason Cummings, Patrick Gray, Larry W. Tjoelker, Munehisa Yabuki
  • Publication number: 20240352152
    Abstract: In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.
    Type: Application
    Filed: April 11, 2024
    Publication date: October 24, 2024
    Inventors: Gregory A. Demopulos, Hans-Wilhelm Schwaeble, Thomas Dudler, Larry W. Tjoelker
  • Publication number: 20240342278
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Application
    Filed: November 29, 2023
    Publication date: October 17, 2024
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas A. Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Patent number: 11883493
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: January 30, 2024
    Assignee: OMEROS CORPORATION
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Publication number: 20220265821
    Abstract: The present invention relates to antibodies that bind the pre-B cell receptor components VpreB and lambda-5, and compositions comprising such antibodies for use in diagnosing and eliminating pre-BCR-expressing leukemia and lymphoma cells. In one aspect, the present invention provides isolated antibodies or an antigen-binding fragment thereof capable of specifically binding to a SLC. The SLC is composed of two noncovalently-linked polypeptides, VpreB and lambda-5.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 25, 2022
    Inventors: Patrick W. GRAY, Larry W. TJOELKER, Christi L. WOOD
  • Publication number: 20210275667
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Application
    Filed: April 27, 2021
    Publication date: September 9, 2021
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Patent number: 11027015
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: June 8, 2021
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Publication number: 20210079117
    Abstract: In one aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, comprising a bioactive peptide amino acid sequence, wherein the bioactive peptide amino acid sequence is an inhibitor of the complement system and is fused to at least one of: (i) the amino terminal region of at least one of: a light chain variable region and/or a heavy chain variable region; or (ii) the carboxy terminal region of at least one of: a light chain constant region and/or a heavy chain constant region, wherein the antibody inhibits complement activation.
    Type: Application
    Filed: August 4, 2020
    Publication date: March 18, 2021
    Inventors: W. Jason Cummings, Patrick Gray, Larry W. Tjoelker, Munehisa Yabuki
  • Publication number: 20200317510
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 8, 2020
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Publication number: 20200270125
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Application
    Filed: April 1, 2020
    Publication date: August 27, 2020
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Patent number: 10745274
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: August 18, 2020
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Patent number: 10639369
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: May 5, 2020
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Publication number: 20180140697
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Application
    Filed: July 31, 2017
    Publication date: May 24, 2018
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Patent number: 9777065
    Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: October 3, 2017
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
  • Patent number: 9677070
    Abstract: The disclosure relates generally to the targeting of genes to, and their integration into, an immunoglobulin (antibody) heavy chain locus. In particular, the methods described herein contemplate replacing the single rearranged heavy chain V, D, and J genes of a B cell lymphoma such as DT40 with independently rearranged VH-D-JH genes of chicken, in a system for generating immunoglobulin diversity. Also contemplated is replacement of the chicken VH-D-JH with rearranged VH-D-JH genes of other vertebrates including human in a system for generating immunoglobulin diversity, with the exception of any substitution disclosed and claimed in PCT application WO 2009/029315 A2. Also described is construction of a diverse chicken immunoglobulin heavy chain VDJ library in DT40 by homologous gene replacement of the single endogenous rearranged VDJ gene with a chicken VDJ repertoire using the described targeting vectors.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 13, 2017
    Assignees: Omeros Corporation, University of Washington Through Its Center for Commercialization
    Inventors: Daniel S. Allison, W. Jason Cummings, John B. Leppard, Nancy Maizels, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Publication number: 20160333107
    Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.
    Type: Application
    Filed: July 1, 2015
    Publication date: November 17, 2016
    Inventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
  • Patent number: 9346888
    Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: May 24, 2016
    Assignee: Omeros Corporation
    Inventors: John Benjamin Leppard, Christi L. Wood, W. Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
  • Patent number: 9102724
    Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: August 11, 2015
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
  • Publication number: 20150017162
    Abstract: In one aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, comprising a bioactive peptide amino acid sequence, wherein the bioactive peptide amino acid sequence is an inhibitor of the complement system and is fused to at least one of: (i) the amino terminal region of at least one of: a light chain variable region and/or a heavy chain variable region; or (ii) the carboxy terminal region of at least one of: a light chain constant region and/or a heavy chain constant region, wherein the antibody inhibits complement activation.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 15, 2015
    Inventors: W. Jason Cummings, Patrick Gray, Larry W. Tjoelker, Munehisa Yabuki
  • Publication number: 20140178385
    Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
    Type: Application
    Filed: November 14, 2013
    Publication date: June 26, 2014
    Applicant: Omeros Corporation
    Inventors: John Benjamin Leppard, Christi L. Wood, W. Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker